Stocks · News reference
InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 11:01 AM
- Checked
- Aug 17, 2026, 11:01 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — InspireMD, Inc. (NSPR)
Filed: 2026-08-17 AccNo: 0001493152-26-038624 Size: 441 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarInspireMD Announces 30-Day Outcomes From CGUARDIANS II Clinical Trial Of CGuard Prime 80cm Implant For Use In Transcarotid Artery Revascularization Procedures
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial
Read original at benzinga